

# Index

## A

- Ablative surgery
  - circumferential excision vs. compartmental resection, 156–157
  - frozen section, 154–155
    - vs. clinical examination, 155–156
    - diagnostic accuracy rate, 154
    - intraoperative decision making, 155
    - lymph nodes, 155
  - oral cavity, surgical access to
    - craniofacial surgery, 158
    - lower cheek flap approaches, 157, 158, 160, 162
    - lower lip-split techniques, 159–161
    - mandibulectomy approach, 157–160
    - peroral approaches, 157–159
    - skin involvement, 162, 165
    - transcutaneous approaches, 158
    - upper cheek flap approaches, 157, 158, 162–164
    - visor flap approaches, 157, 158, 162
  - surgical margins
    - clinical implications, 152–153
    - definition, 148–149
    - factors determination, 149–150
    - field cancerization, 150–151
    - invasion pattern, 151–152
    - positive margin, 148
    - tumor extension, mechanism of, 150
- ACE-27 Index, 237, 238
- ACOSOG trial, 222, 223
- Adjuvant chemotherapy, 263
- Adjuvant radiotherapy
  - indications, 109–112
  - management guidelines, oral cancer, 88
  - mucositis, 260–262
  - N0 neck, 198
  - paradigm development, 109–112
  - prognostic factors, 112–113

- risk assessment, 112–113
- skin reactions, 262–263
- timing of, 112

American Joint Society of Cancer Control (AJCC), 11, 12, 30, 81

Antiapoptotic molecules, 295

## B

- Biomarkers, 17–18, 309
- Blue dye technique, 213–214
- Blunt dissection techniques, 272
- Brachytherapy (BRT), 96–98, 288–289
- Buccal mucosa cancer, 175–176

## C

- Cancer stem cells (CSC), 152, 292
- Carboplatin, 129, 132
- CCL2-AMPK-mTORC1-survivin pathway, 309
- Cell cycle check points, 295
- Cetuximab, 301–304
- Chemotherapy
  - cetuximab, 133
  - concomitant radiation
    - applicability, 135
    - evidence, 133–134
    - OCAT, 135
    - primary curative management, 135–136
    - recommended regimen, 134–135
  - cytotoxic, 127–128
  - 5-FU, 132
  - induction therapy
    - resectable disease, 136–137
    - technically unresectable disease, 139
    - unresectable disease, 137–138
  - MTX, 133
  - in palliation

- Chemotherapy (*cont.*)
- chemotherapy and targeted agent, 140–141
  - combination therapy, 138
  - metronomic chemotherapy, 141
  - platinum agents, 129–131
  - recurrent oral cancer, 282
  - side effects, 127
- Cisplatin, 129, 134–137, 139, 141, 263, 282
- Clinical evaluation
- anatomy, 5–6
  - ancillary services, 8
  - biomarkers, 17–18
  - examination, 4
  - histologic characteristics, 16–17
  - history, 1–2
  - imaging, 6–7
  - neck, 16
  - oral cavity lesions
    - adjuvant examination techniques, 9
    - erythroplakia, 8, 9
    - GB sulcus with skin infiltration, 11
    - kaposi sarcoma, 10
    - leukoplakia, 8, 9, 12
    - lichen planus, 8, 9
    - minor salivary gland tumor, 10
    - mucosal melanoma, 10
    - necrotizing sialometaplasia, 8–9
    - oral dysplasia, 9
    - sarcoma, 10
    - squamous cell carcinoma, 10
    - submucosal fibrosis, 8, 9
    - tongue carcinoma, early stage, 12
    - verrucous hyperplasia, 8
  - risk factors, 3
- Combination therapy, 138
- Coronoidectomy, 274
- Craniofacial surgery, 158
- CSC. *See* Cancer stem cells (CSC)
- Cyclooxygenase (COX), 304–307
- Cytotoxic chemoradiotherapy. *See* Genotoxic chemoradiotherapy
- D**
- Disease-specific survival (DSS), 15, 106, 224
- Docetaxel, 129, 132, 138, 140, 300
- Drug metabolism, 295
- E**
- EBRT. *See* External beam radiation therapy (EBRT)
- Epithelial-mesenchymal transformation (EMT), 292
- External beam radiation therapy (EBRT), 87, 88, 96–97, 118, 120, 289
- Extracapsular extension (ECE), 17, 110
- F**
- Fine needle aspiration biopsy (FNAB), 52, 194
- G**
- GBS. *See* Gingivo-buccal sulcus complex (GBS)
- Genotoxic chemoradiotherapy
- drug resistance, 294–295
  - markers
    - molecular evidence, 296–301
    - in vitro evidence, 296
  - resistance-response patterns, 293
- Gingivo-buccal sulcus complex (GBS), 174–178
- H**
- Head and neck region, anatomy of, 23–24
- Head and neck squamous cell carcinoma (HNSCC)
- adjuvant radiotherapy, 111
  - anti-EGFR therapy, 304
  - cetuximab, 133
  - COX-2, 305, 306
  - cytotoxic chemotherapy, 127–128
  - European phase II SBRT trial, 105
  - FDG PET CT, 60–62, 72–74
    - benefits of, 74
    - distant metastases detection, 65
    - impact, 66–67
    - left buccal mucosa, 61
    - left oropharynx, 63, 64
    - pre-PET and post-PET management plans, 65
    - synchronous second tumor
      - detection, 65
      - tongue, 62
  - induction chemotherapy, 109
  - mTOR signaling, 307–309
  - p53, altraction in, 296
  - radiotherapy, 105
  - radiotherapy planning, 67, 73
  - risk factors, 3
  - surveillance/detection, of recurrence, 63, 72
  - targeted therapies, 301
  - taxanes, 129
  - unknown primary tumor diagnosis, 59–60
- Hemimandibulectomy, 28

High dose rate (HDR), 87, 97, 98  
 HNSCC. *See* Head and neck squamous cell carcinoma (HNSCC)  
 Human papillomavirus (HPV), 3

**I**

Image-guided radiation therapy (IGRT), 99, 102–104  
 IMRT. *See* Intensity-modulated radiation therapy (IMRT)  
 Induction chemotherapy, 109  
 Infra-hyoid release technique, 173  
 In situ recurrences, 292  
 Intensity-modulated radiation therapy (IMRT), 98, 100–102, 109, 118, 119, 288  
 Intrinsic cisplatin sensitivity (ICS), 296  
 Involve infratemporal fossa (ITF), 47, 48, 178, 180, 181

**K**

Kaposi sarcoma, 10

**L**

Larynx suspension technique, 173  
 Loss of heterozygosity (LOH), 296  
 Low-dose rate (LDR), 87, 96–98  
 Lower cheek flap approaches, 157, 158, 160, 162  
 Lower lip-split techniques, 159–161  
 Lymphoscintigraphy  
   intraoperative handheld gamma probe, 215  
   marked on neck, 215  
   preoperative dynamic, 214  
   radioisotopes, 216  
   SLN, 214, 215

**M**

Macrometastasis, 219  
 Mammalian targets of rapamycin (mTOR) signaling, 307–311  
 Management guidelines, oral cancer, 82, 83  
   adjuvant treatment, 88  
   critical decisions, 82  
   curative intent treatment, 82–85  
   diagnosis, 81  
   evaluation, 81  
   evidence-based guidelines, 80  
   NCCN guidelines, 80  
   palliative intent treatment

  performance status assessment, 89–90  
   resectability assessment, 88  
 primary tumor treatment  
   adequate resection, 85  
   contralateral neck, 87  
   mandible management, 85–86  
   node-positive neck, 87  
   N-positive neck, 86  
   oral tongue, 85  
   primary radiotherapy, 87  
   skin management, 86  
   recurrences management, 90  
   staging, 81–82  
   surveillance, 90  
 Mandibular retromolar malignancies, 24  
 Mandibulectomy, 157–160, 166  
 Mandibulotomy, 274  
 Marginal mandibulectomy, 160, 162, 166, 167, 174, 176, 178–180, 247, 248, 250  
 Metabolic tumor volume (MTV), 194  
 Metronomic chemotherapy, 141  
 Micrometastasis, 219, 220, 225, 226  
 Microvascular technique, 275  
 Minimally invasive surgery, 157  
 Modified radical neck dissections (MRND), 198–203  
 mTOR signaling. *See* Mammalian targets of rapamycin (mTOR) signaling  
 Mucositis, 260–262  
 Multidetector computed tomography (MDCT) imaging, 27, 37, 39, 46, 49  
 Multi-leaf collimator (MLC), 98, 100

**N**

National Comprehensive Cancer Network (NCCN), 7, 80, 109, 110, 198, 264  
 Neck, management of  
   anatomy, 190–191  
   diagnosis, 191–194  
   N0 neck  
     adjuvant therapy, 198  
     management, 194–197  
     surgical technique, 197–198  
   N-positive neck  
     management, 198–200  
     surgical technique, 200–203  
   recurrent disease, 203–206  
   TNM staging, 191–194  
 Necrotizing sialometaplasia, 8–9  
 Neo-adjuvant chemotherapy (NACT), 296  
 Nephrotoxicity, 263  
 Nerve injury, 85, 243–245  
 Nodal metastasis, 15, 83–84  
 Non-small cell lung cancer (NSCLC), 300

**O**

- OCSCC. *See* Oral cavity squamous cell carcinoma (OCSCC)
- Oral cancer adjuvant treatment (OCAT), 135
- Oral cavity imaging
- alveolar process, 26
  - axial and coronal contrast-enhanced images, 27, 29
  - CT and MR images, 27, 42
  - imaging assessment, 29–32
  - imaging modalities
    - elevated lesion, 36, 38
    - extensive malignant lesion, 36, 37
    - lesion location, 35, 36
    - MDCT, 33, 37, 39
    - mid-cavity level, 33
    - pan tomography, 33
    - PCT, 33, 34, 39
    - SPECT radionuclide imaging, 41
    - submucosal lesion, 36, 38
    - ultrasound, 42
  - individual subsite import imaging
    - considerations, 44
  - infratemporal fossa, 26
  - ITF, 47, 48
  - mandibular/maxillary invasion, 44–46
  - mandibular retromolar malignancies, 24
  - masticator space, 26
  - mucosa, 24
  - neck node evaluation, 43–44
  - neck nodes, 52–58
  - oral cavity lesions, TNM classification, 42–43
  - palate, 46–47
  - posterior tongue, 27, 30
  - pterygomandibular raphe, 24
  - pterygopalatine fossa, 26
  - RMT, 24, 27, 28, 52–55
  - sigmoid notch, 26
  - sublingual space, 25–26
  - submandibular space, 25
  - tongue, 24, 25, 27, 31, 47–52
  - tumor spread pathway, 27–28
- Oral cavity squamous cell carcinoma (OCSCC)
- ablative surgery (*see* Ablative surgery)
  - buccal mucosa cancer, 175–176
  - CT-RT, 148
  - early stage, 147
  - GBS, 174–178
  - HPV, 18
  - IMRT, 101
  - induction chemotherapy, 109
  - infra-hyoid release technique, 173

- invasive tongue cancer, 171, 172
  - larynx suspension technique, 173
  - N0 neck, 211
  - optimum margin, 170
  - peroral approach, 167, 170–172
  - posterior GBS, 178–183
  - preoperative (chemo)-radiotherapy, 108
  - primary surgery, 148
  - radiotherapy, 105
  - RMT, 178–183
  - surveillance in, 264–266
  - tongue and FOM lesion, 164–169, 173–174
  - T staging, 57
  - upper alveolus and hard palate, 180, 182–184
  - visor flap approach, 172, 173
  - WLE procedure, 167, 171
- Oral dysplasia, 8
- Osteoradionecrosis (ORN), 254

**P**

- Patient evaluation
- general evaluation, 236–238
  - neck and surgical planning, 238–239
- Peroral approaches, 157–159, 167, 170–172
- Positive neck disease, 84
- Puffed cheek technique (PCT), 33, 34, 36, 38, 39

**Q**

- Quality of life (QOL), 118, 220, 221

**R**

- Radiation Therapy Oncology Group (RTOG), 107–110, 134, 263, 285, 288
- Radical neck dissection (RND), 198, 201, 202, 204–206
- Radiotherapy (RT), 98–99
- adjuvant radiotherapy, 95
  - indications, 109–112
  - paradigm development, 109–112
  - prognostic factors, 112–113
  - risk assessment, 112–113
  - timing of, 112
- altered fractionation, 107–108
- BT, 96–97
- combined modality therapy, 120
- definitive RT, 106
- 3DRT, 100–102

- EBRT, 96–97
- experience matters and outcomes, 105
- HNC, 65, 73
- IGRT, 102–104
- IMRT, 100–102
- induction chemotherapy, 109
- intraoral devices, 99
- neck, management of, 106–107
- origins of, 95–96
- osteoradionecrosis, 119
- preoperative (chemo)-radiotherapy, 108
- primary tumor, 84, 87
- recurrent oral cancer
  - BRT, 288–289
  - IMRT, 288
  - indications, 284, 285
  - left retromolar trigone, 283, 286, 287
  - recurrent T2N1M0 SCCA, 283–285
  - RTOG, 285, 288
- repeat irradiation, 109
- SBRT, 104–105
- secondary malignancy, 119–120
- sequelae of, 118
- site-specific outcomes
  - buccal mucosa, 114
  - FOM, 115–117
  - hard palate, 117
  - mucosal lip and alveolar ridge, 113
  - oral tongue, 117–118
  - RMT, 114–115
- thermoplastic mask, 97–98
- xerostomia, 118–119
- Recurrent oral cancer
  - radiation therapy
    - BRT, 288–289
    - IMRT, 288
    - indications, 284, 285
    - left retromolar trigone, 283, 286, 287
    - recurrent T2N1M0 SCCA, 283–285
    - RTOG, 285, 288
  - surgical treatment and reconstruction
    - chemotherapy, 282
    - functional surgery, 273–274
    - perioperative care, 283
    - recurrence detection, 271–272
    - reoperative head and neck surgery, 274–281
    - subsite-based biologic behavior, 273
    - surgical technique, modifications of, 272–273
    - vascular technique, 275
- Retromolar trigone (RMT), 24, 27, 28, 52–55, 114–115, 174, 178–183
- RND. *See* Radical neck dissection (RND)
- Routine histopathologic evaluation (HPE), 217–220
- RTOG. *See* Radiation Therapy Oncology Group (RTOG)
- S**
- Scar recurrence, 292–293
- Segmental mandibulectomy, 28, 166
- Selective neck dissection (SND), 220, 223, 225, 227
- Sentinel lymph node (SLN), 213–215, 217, 220, 225–227
- Sentinel lymph node biopsy (SNB)
  - advantages, 217, 224–225
  - blue dye technique, 213–214
  - concept, 212
  - diagnostic efficacy
    - accuracy, 222–223
    - occult metastasis detection, 222
    - sentinel lymph node identification, 221–222
  - evolution, 213
  - ICG-(99m)Tc-nanocolloid, 227
  - limitations, 225–226
  - lymphoscintigraphy
    - intraoperative handheld gamma probe, 215
    - marking, on neck, 215
    - preoperative dynamic, 214
    - radioisotopes, 216
    - SLN, 214, 215
  - morbidity, 219–221
  - NCCN guidelines, 80
  - NIR fluorescence imaging, 226
  - pathological evaluation
    - frozen section, 217
    - HPE, 217–220
    - imprint cytology, 217
    - SSS, 217–220
  - PET-CT, 226
  - recurrence and survival outcomes, 223–224
  - SND, 227
- Serial step sectioning (SSS), 217–220
- SLN. *See* Sentinel lymph node (SLN)
- SMAS. *See* Submucous aponeurotic system (SMAS)
- SNB. *See* Sentinel lymph node biopsy (SNB)
- SND. *See* Selective neck dissection (SND)
- Stereotactic body radiation therapy (SBRT), 99, 104–105
- Submucous aponeurotic system (SMAS), 174, 175

